Ganguli R, Yang Z, Shurin G, Chengappa K N, Brar J S, Gubbi A V, Rabin B S
Department of Psychiatry, University of Pittsburgh School of Medicine, PA.
Psychiatry Res. 1994 Jan;51(1):1-10. doi: 10.1016/0165-1781(94)90042-6.
Using an enzyme immunoassay (ELISA), we measured serum interleukin-6 (IL-6) concentration in 128 schizophrenic patients (24 of whom were never medicated) and in 110 normal control subjects. Mean serum IL-6 concentration was significantly higher in the schizophrenic patients as compared with the control subjects (p = 0.009). Comparisons within the patient group revealed that serum IL-6 was significantly correlated with duration of illness (r = 0.32, p = 0.0004). After covariation for duration of illness, there was no relationship between IL-6 levels and the production of autoantibodies, clinical state, or medication status. Thus, elevated serum IL-6 levels in schizophrenia develop during the course of illness and may be related to treatment or to disease progression.
我们采用酶联免疫吸附测定(ELISA)法,检测了128例精神分裂症患者(其中24例从未接受过药物治疗)和110名正常对照者的血清白细胞介素-6(IL-6)浓度。与对照者相比,精神分裂症患者的平均血清IL-6浓度显著更高(p = 0.009)。患者组内比较显示,血清IL-6与病程显著相关(r = 0.32,p = 0.0004)。在对病程进行协变量调整后,IL-6水平与自身抗体产生、临床状态或用药情况之间无相关性。因此,精神分裂症患者血清IL-6水平升高是在病程中出现的,可能与治疗或疾病进展有关。